[Molecular pharmacology on DNA methylating agent temozolomide].

No abstract is available for this paper.

• Publication year

  2007

• Venue

  No shinkei geka. Neurological surgery

• Publication date

  2007-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 17310751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models

  2009cited by this paper
• Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

  2008cited by this paper
• Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.

  2006cited by this paper
• A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

  2006cited by this paper
• Targeted Modulation of MGMT: Clinical Implications

  2006cited by this paper
• Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas

  2005cited by this paper
• Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Drug Insight: temozolomide as a treatment for malignant glioma—impact of a recent trial

  2005cited by this paper
• Mutations in Rb1 pathway-related genes are associated with poor prognosis in Anaplastic Astrocytomas

  2005cited by this paper
• MGMT: its role in cancer aetiology and cancer therapeutics

  2004cited by this paper
• The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

  2004cited by this paper
• Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

  2004cited by this paper
• O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas.

  2004cited by this paper
• Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.

  2004cited by this paper
• Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model

  2004cited by this paper
• DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitrosocompounds

  2004cited by this paper
• Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.

  2003cited by this paper
• The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents

  2003cited by this paper
• Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.

  2003cited by this paper
• Activation of Akt/Protein Kinase B Overcomes a G2/M Cell Cycle Checkpoint Induced by DNA Damage

  2002cited by this paper
• A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle.

  2002cited by this paper
• Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

  2002cited by this paper
• Forkhead transcription factors contribute to execution of the mitotic programme in mammals

  2001cited by this paper
• Ten years of protein kinase B signalling: a hard Akt to follow.

  2001cited by this paper
• Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

  2001cited by this paper
• Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.

  2001cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.

  2000cited by this paper
• Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

  2000cited by this paper
• Inhibition of CDKs as a Therapeutic Modality

  2000cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• UCN‐01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation

  2000cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000cited by this paper
• The G2-phase DNA-damage checkpoint.

  2000cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000cited by this paper
• Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice

  2000cited by this paper
• Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene

  2000cited by this paper
• The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

  2000cited by this paper
• Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.

  2000cited by this paper
• Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds

  1999cited by this paper
• Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

  1999cited by this paper
• Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs

  1999cited by this paper
• Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage.

  1999cited by this paper
• Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

  1999cited by this paper
• Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide

  1999cited by this paper
• The G2 Checkpoint Is Maintained by Redundant Pathways

  1999cited by this paper
• Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

  1999cited by this paper
• 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage.

  1999cited by this paper
• p53 regulates a G2 checkpoint through cyclin B1.

  1999cited by this paper
• Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.

  1998cited by this paper
• Involvement of the mismatch repair system in temozolomide-induced apoptosis.

  1998cited by this paper
• Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T‐cell leukemia line tolerant to methylating agents

  1998cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1

  1998cited by this paper
• Checkpoint pathways come of age.

  1997cited by this paper
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

  1997cited by this paper
• Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells.

  1997cited by this paper
• Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.

  1997cited by this paper
• Understanding and manipulating O6-methylguanine-DNA methyltransferase expression.

  1997cited by this paper
• Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.

  1997cited by this paper
• Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

  1997cited by this paper
• Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.

  1997cited by this paper
• Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma

  1997cited by this paper
• A new look at the role of p53 in leukemia cell sensitivity to chemotherapy

  1997cited by this paper
• Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.

  1997cited by this paper
• UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

  1996cited by this paper
• Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

  1996cited by this paper
• Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

  1996cited by this paper
• Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.

  1995cited by this paper
• Advances in chemotherapy for brain tumors.

  1995cited by this paper
• Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.

  1995cited by this paper
• Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients.

  1995cited by this paper
• Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

  1995cited by this paper
• A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

  1995cited by this paper
• DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines.

  1995cited by this paper
• Cell cycle regulation of the p34cdc2 inhibitory kinases.

  1994cited by this paper
• Mitosis in transition.

  1994cited by this paper
• DNA damage tolerance, mismatch repair and genome instability

  1994cited by this paper
• NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

  1994cited by this paper
• Analysis of the p53 gene and its expression in human glioblastoma cells.

  1994cited by this paper
• Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage

  1993cited by this paper
• Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

  1993cited by this paper
• An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.

  1993cited by this paper
• Clonal expansion of p53 mutant cells is associated with brain tumour progression

  1992cited by this paper
• Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15.

  1992cited by this paper
• Self-destruction and tolerance in resistance of mammalian cells to alkylation damage.

  1992cited by this paper
• Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

  1992cited by this paper
• The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

  1990cited by this paper
• Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data.

  1986cited by this paper
• Purification and properties of O6-methylguanine-DNA transmethylase from rat liver.

  1983cited by this paper
• Mismatch correction at O6-methylguanine residues in E. coli DNA

  1982cited by this paper

• Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells

  2010cites this paper
• Temozolomide-Induced Myelodysplasia

  2010cites this paper